Mesoblast
Chemicals & Related Products · Australia · 51-200 Employees
View Company Info for Free
Overview
Headquarters
L 38 55 Collins St, Melbourne, Victoria,...Phone Number
+61396396036Website
www.mesoblast.comRevenue
$120.3 MillionStock Symbol
MSBIndustry
ZI Rank: 4
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
9
6
4
4
4
About Mesoblast
Founded in 2004, Mesoblast, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. They offer products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. The company is headquartered in Melbourne, Victoria, Australia.Explore more
Mesoblast Org Chart
Get the full picture
Sign in to uncover key details.
RB
Therapeutic Business Unit, Musculoskeletal Re...
SH
National Director, Medical Science Liaison Te...
JG
Medical Director, Medical Affairs, Immunology...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mesoblast your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Mesoblast has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Mesoblast
Funding: Get notified immidiatlly once Mesoblast has new funding data
Website visits: Recent activity has been detected on your website
Mesoblast, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Mesoblast recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Mesoblast is spiking on competitors!
Product Launch: Get notified when Mesoblast launches new products
Click to see if Mesoblast had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Mesoblast as Masked Content
Find 3 more new buyers
Compare Similar Companies to Mesoblast
Compare insights from companies similar to Mesoblast, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Mesoblast financials insights
Gather financial insights about Mesoblast, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$68.3M
2017
Share Placement
$40M
2018
Debt
$75M
2019
Share Placement
$51M
2020
Share Placement
$90M
2021
Corporate Investment
$110M
2025
Share Placement
$260M
Stock/Share Issuance
$50M
Mesoblast Tech Stack
A closer look at the technologies used by Mesoblast
Most Recent Scoops
Project
Mesoblast has received FDA clearance of an Investigational New Drug (IND) application to commence a Phase III trial for RYONCIL (remestemcel-L) in Duchenne muscular dystrophy, a rare inflammatory condition affecting children as young as 2 to 3 years old, leveraging the product's existing approval and mechanism of action.
Pharmaceuticals, Clinical Operations
Earnings
ended fiscal year 2026 with $103 million in cash, reporting net cash usage of $43.8 million for the year, with second-half cash burn of $13.4 million compared to $50 million in the same period of the prior fiscal year.
Earnings, Business Finance, Finance
Project
Mesoblast has completed enrollment of 350 patients in its pivotal randomized controlled Phase III trial for chronic low back pain, with total patient numbers increased from 300 to 350 due to strong demand from trial investigators.
Clinical Operations
Project
Mesoblast is advancing its second-generation platform, rexlemestrocel-L, targeting local delivery applications in inflammatory heart disease and orthopedic conditions, particularly intervertebral disc disease, where a single injection has demonstrated substantial and durable long-term pain reduction, with combined total addressable markets in cardiac disease and chronic back pain exceeding $20 billion.
Medical Research, Pharmaceuticals
Person-Based
Pharmaceuticals, Clinical Operations
Mesoblast News & Media
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
Mesoblast Limited (MESO) Q4 2026 Earnings Call August 26, 2026 6:30 PM EDTCompany ParticipantsSilviu Itescu - Founder, CEO, MD, Chairman of Scientific...Mesoblast Reports Substantial Revenue Growth to US$120M
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes TreatmentMesoblast Financial Results and Corporate Update Webcast
NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026.Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with the inflammatory condition of degenerative disc disease. The major milestone was achieved with 350 patients randomized and treated with either an intra-di
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Mesoblast
Sign Up For FreeTo access detailed company insights
Founded in 2004, Mesoblast, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. They offer products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. The company is headquartered in Melbourne, Victoria, Australia.... Read More
